A longitudinal study design, assessing the disease course and T-cell activation of MS patients before and during treatment with IFN-β would have made it easier to correlate IFN-β-induced immune effects and examine the extent to which they correlate with the clinical response to treatment. The gene discussed is IFNB1; the disease is myeloid sarcoma.